Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal

The Firm is investigating legal claims on behalf of alleged victims of Risperdal and gynecomastia, or male breast growth.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Free Case Review
Our Firm has heard from a number of individuals who are concerned about a possible connection between Risperdal and gynecomastia. We look forward to more progress in the Risperdal litigation underway in Pennsylvania.

New York, New York (PRWEB) December 03, 2013

Hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/), including many that allege a link between Risperdal and gynecomastia (male breast growth), continue to move forward in a consolidated litigation underway in the Pennsylvania Court of Common Pleas in Philadelphia. According to a Motion filed on November 26, 2013, Johnson & Johnson has asserted that plaintiffs are improperly seeking to publicly release data concerning some Risperdal clinical studies. The studies, which were sealed via a court order in 2011, are exempt from public access because they were never filed with the court, or determined to be public records, the Motion states. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm has heard from a number of individuals who are concerned about a possible connection between Risperdal and gynecomastia. We look forward to more progress in the Risperdal litigation underway in Pennsylvania,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently evaluating Risperdal lawsuits on behalf of men and boys who may have developed gynecomastia due to their use of the drug.

Risperdal and Gynecomastia
Risperdal is an antipsychotic medication that has been on the market since 1993, and is used to treat a number of psychiatric ailments in adults and children. According to court documents, Plaintiffs who have filed claims alleging a connection between Risperdal and Gynecomastia also allege that Johnson & Johnson concealed this association and improperly marketed the drug for use in children. In October 2012, Bloomberg.com reported that Johnson & Johnson had agreed to settle five Risperdal lawsuits filed in the Pennsylvania litigation involving gynecomastia allegations.*

On November 4th, the U.S. Department of Justice announced it had reached an agreement with Johnson & Johnson and its Janssen Pharmaceuticals unit to settle criminal and civil charges regarding the marketing of Risperdal and other drugs. According to court documents filed in the case, federal prosecutors had alleged that the company knew of the possible association between Risperdal and gynecomastia. The government also charged that Johnson & Johnson and Janssen marketed Risperdal for pediatric uses long before the drug was approved for such indications. Under the settlement, Johnson & Johnson will pay a total of $2.5 billion in criminal and civil penalties. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Alleged victims of Risperdal and gynecomastia may be entitled to compensation for any damages related to their injuries, including medial bills, lost wages, pain and suffering, and emotional distress. To learn more about the possible association between Risperdal and male breast growth, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author